Pharmaceutical Technology-08-01-2012

Outsourcing Resources

The manufacturing capacity-sharing model in biologics and Merck & Co. and MedImmune ushers in a new paradigm of "co-opetition".

The author provides results and commentary on a survey analyzing outsourcing strategies, practices, challenges, and outcomes in the selection of a CRO.

An examination of the current and projected market for biosimilars, development costs for biosimilars compared with small-molecule generic drug, and partnerships in biosimilars.

The author discusses how a CDMO helps in gaining process understanding and in developing robust, high-quality products and processes.

The authors highlight costs, benefits, and implementation success factors across first, second, and third generations of facility management outsourcing contracts.

AMRI, a contract research and manufacturing organization, discusses its adaption of an insourcing model with Eli Lilly.

Annual survey shows strong growth for service providers and promises to continue into 2013.